Open AccessOutcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period
Author(s) -
Xiayu Jiao,
Joel W. Hay,
Sarmad Sadeghi,
Afsaneh Barzi
Publication year - 2020
Publication title -
american journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.896
H-Index - 78
eISSN - 1537-453X
pISSN - 0277-3732
DOI - 10.1097/coc.0000000000000684
Subject(s) - medicine , oxaliplatin , hazard ratio , proportional hazards model , confidence interval , epidemiology , colorectal cancer , oncology , surgery , stage (stratigraphy) , cancer , paleontology , biology
Previous SEER (Surveillance, Epidemiology, and End Results)-Medicare analyses have shown no definitive survival benefit for adjuvant chemotherapy (AC) with fluoropyrimidines. Impact of oxaliplatin-containing regimens for elderly stage II patients in real-world setting is unknown. We explored the utilization and outcome of AC after the Food and Drug Administration (FDA) approval of oxaliplatin.